Novo Nordisk pays $200M upfront for United Laboratories International Holdings' triple-G obesity shot

Novo Nordisk is not immune to the trend of seeking obesity assets from China-based biotechs, and the Danish drugmaker will pay United Laboratories International Holdings $200 million upfront for an exclusive ...

Related Posts

Luxa's stem cell therapy for dry AMD shows early promise

Mar 6, 2025  0

Roche unveils plans for its DNA sequencer that's been 1...

Feb 20, 2025  0

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai a...

Feb 28, 2025  0

Comments

Name

Email

Comment

Post Comment